Key insights
- Doximity shares face pressure after Baird downgraded the stock due to a weak fiscal 2027 outlook, concerns about AI spending, and slowing pharmaceutical advertising. The downgrade reflects increasing competition and softer demand, suggesting a potential slowdown in growth for the healthcare technology sector, which could negatively impact investor sentiment towards similar companies.
Investing.com -- Shares of Doximity came under renewed pressure after slew of Wall Street firms downgraded the healthcare technology company following a disappointing fiscal 2027 outlook and growing concerns over AI-related spending and slowing pharmaceutical advertising demand.
Baird downgraded Doximity to “Neutral” from “Outperform” and slashed its price target to $18 from $40, noting that the company faces a “very long road ahead” before its AI investments generate meaningful returns. Analysts cited increasing competition, softer demand trends, leadership changes, and continued pressure on investor sentiment.